MX2009004178A - Conjugados peptidicos citotoxicos. - Google Patents

Conjugados peptidicos citotoxicos.

Info

Publication number
MX2009004178A
MX2009004178A MX2009004178A MX2009004178A MX2009004178A MX 2009004178 A MX2009004178 A MX 2009004178A MX 2009004178 A MX2009004178 A MX 2009004178A MX 2009004178 A MX2009004178 A MX 2009004178A MX 2009004178 A MX2009004178 A MX 2009004178A
Authority
MX
Mexico
Prior art keywords
peptide
cytotoxic conjugates
conjugates
cytotoxic
neoplasia
Prior art date
Application number
MX2009004178A
Other languages
English (en)
Inventor
Christophe Alain Thurieau
Yeelana Shen
Zheng Xin Dong
Michael Dewitt Culler
Jundong Zhang
Sun Hyuk Kim
Original Assignee
Ipsen Pharma Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma Sas filed Critical Ipsen Pharma Sas
Publication of MX2009004178A publication Critical patent/MX2009004178A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención presenta compuestos citotóxicos dirigidos y métodos relacionados con su uso terapéutico para el tratamiento de neoplasia y otros padecimientos.
MX2009004178A 2006-10-20 2007-10-17 Conjugados peptidicos citotoxicos. MX2009004178A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85314006P 2006-10-20 2006-10-20
US91813307P 2007-03-15 2007-03-15
PCT/US2007/022179 WO2008051421A2 (en) 2006-10-20 2007-10-17 Peptide-cytotoxic conjugates

Publications (1)

Publication Number Publication Date
MX2009004178A true MX2009004178A (es) 2009-09-07

Family

ID=39325115

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004178A MX2009004178A (es) 2006-10-20 2007-10-17 Conjugados peptidicos citotoxicos.

Country Status (14)

Country Link
US (1) US8236762B2 (es)
EP (1) EP2084178B1 (es)
JP (1) JP4988851B2 (es)
KR (1) KR20090074806A (es)
AT (1) ATE536368T1 (es)
AU (1) AU2007309585B2 (es)
BR (1) BRPI0718287A2 (es)
CA (1) CA2666991A1 (es)
ES (1) ES2378902T3 (es)
IL (1) IL198202A0 (es)
MX (1) MX2009004178A (es)
NZ (1) NZ577039A (es)
RU (1) RU2457218C2 (es)
WO (1) WO2008051421A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004232314B2 (en) * 2003-04-22 2007-11-22 Ipsen Pharma S.A.S. Peptide vectors
JP5584236B2 (ja) * 2009-02-20 2014-09-03 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ 神経ペプチドｙ受容体結合化合物を有する細胞毒性コンジュゲート
US9447125B2 (en) 2012-08-16 2016-09-20 Momentive Performance Materials Inc. Reusable homogeneous cobalt pyridine diimine catalysts for dehydrogenative silylation and tandem dehydrogenative-silylation-hydrogenation
US9371340B2 (en) 2012-08-16 2016-06-21 Momentive Performance Materials Inc. Dehydrogenative silylation, hydrosilylation and crosslinking using cobalt catalysts
WO2022035843A1 (en) * 2020-08-12 2022-02-17 Nanomedicine Innovation Center, Llc Topoisomerase inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1589151A (zh) * 2001-09-21 2005-03-02 图兰恩教育基金管理人 诊断或治疗性促生长素抑制素或铃蟾肽类似物的连接物及其用途
JP4579235B2 (ja) * 2003-04-11 2010-11-10 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ ソマトスタチン−ドーパミンキメラ類似体
AU2004232314B2 (en) * 2003-04-22 2007-11-22 Ipsen Pharma S.A.S. Peptide vectors

Also Published As

Publication number Publication date
EP2084178A2 (en) 2009-08-05
NZ577039A (en) 2011-11-25
WO2008051421A3 (en) 2008-12-11
AU2007309585B2 (en) 2011-11-17
EP2084178B1 (en) 2011-12-07
KR20090074806A (ko) 2009-07-07
WO2008051421A2 (en) 2008-05-02
CA2666991A1 (en) 2008-05-02
JP2010506924A (ja) 2010-03-04
AU2007309585A1 (en) 2008-05-02
US8236762B2 (en) 2012-08-07
ATE536368T1 (de) 2011-12-15
IL198202A0 (en) 2011-08-01
RU2009118961A (ru) 2010-11-27
BRPI0718287A2 (pt) 2013-11-19
JP4988851B2 (ja) 2012-08-01
EP2084178A4 (en) 2009-10-28
US20100113367A1 (en) 2010-05-06
RU2457218C2 (ru) 2012-07-27
ES2378902T3 (es) 2012-04-18

Similar Documents

Publication Publication Date Title
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
EP2043679A4 (en) CYTOTOXIC T-LYMPHOCYTE INDUCTIVE IMMUNOGENES FOR THE PREVENTION, TREATMENT AND DIAGNOSIS OF CANCER
EP2061503A4 (en) IMMUNOGENS INDUCING THE PRODUCTION OF CYTOTOXIC T CELLS FOR THE PREVENTION, TREATMENT AND DIAGNOSIS OF CANCER
MX2009006706A (es) Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
TNSN08283A1 (en) Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
EP2125855A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES
MY198422A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
PL2134704T3 (pl) Związki i kompozycje pełniące rolę modulatorów aktywności GPR119
MY151048A (en) Use of flibanserin for the treatment of post-menopausal sexual desire disorders
TN2011000291A1 (en) Purine compounds
IN2012DN00869A (es)
MX2010000098A (es) Derivados de guanina policiclicos y sus metodos de uso.
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
MX2010001449A (es) Bromhidrato de bupropion y aplicaciones terapeuticas.
MX2010001300A (es) Uso de hesperidina o un derivado de la misma para prevencion y/o tratamiento de pieles flacidas.
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
SI2024368T1 (sl) Derivati 6,7,8,9-tetrahidro-5h-pirimido(4,5-d)azepin-4-il)-amina kot modulatorji trpv 1 za zdravljenje boleäśine
CY1115725T1 (el) Ενωσεις, συνθεσεις και μεθοδοι για την θεραπευτικη αγωγη των βητα-αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων
MX2010002736A (es) Derivados de 1-amino-alquilciclohexano para el tratamiento de tinnitus coclear.
WO2010121164A3 (en) 1,4-benzodiazepinone compounds and their use in treating cancer
UA107204C2 (uk) Протигрибкова композиція, що містить грибковий організм pythium oligandrum
WO2010074936A3 (en) Enzastaurin for the treatment of cancer
IL198202A0 (en) Peptide-cytotoxic conjugates

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration